The three state-of-the-art manufacturing units within our plant, are segregated and dedicated to the production of conventional solid dosage forms and oncology sterile liquid dosage and solid dosage forms.
Conventional: 780M tablets, 260M capsules, 7,5M glass vials
Oncology: 75M tablets & capsules, 17M glass vials
While GENEPHARM retains its position in the Greek market, having established solid relationships with local physicians and patients, our business extends globally via strategic alliances, based on the development of new products and our continuous investment in state-of-the-art infrastructure and technologies.
Today, our presence extends to over 90 countries through our collaboration with some of the most respected pharmaceutical companies in the world.